Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus

American Journal of the Medical Sciences

Volumn 341, Issue 2, 2011, Pages 92-95

  Nakhjavani, Manouchehr ^a   Asgharani, Firouzeh ^a   Khalilzadeh, Omid ^a   Esteghamati, Alireza ^a   Ghaneei, Azam ^a   Morteza, Afsaneh ^a   Anvari, Mehdi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; LCAT activity; Ox LDL

Indexed keywords

CREATININE; GLUCOSE; INSULIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 79951518173     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181f3ce10     Document Type: Article

References (38)

1. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69. (Pubitemid 38019139)
2. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development ofischaemic heart-disease. Lancet 1975;1:16-9.
3. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor ofcoronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesteroltransport. Atherosclerosis 1996;124(suppl):S11-20.
4. Lehto S, Ronnemaa T, Haffner SM, et al. Dyslipidemia and hyper-glycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9. (Pubitemid 27315286)
5. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27. (Pubitemid 32061923)
6. von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Curr Opin Cardiol 2000;15:348-54.
7. Quintao EC, Medina WL, Passarelli M. Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000;16:237-50. (Pubitemid 30611784)
8. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96: 1221-32. (Pubitemid 40962099)
9. Fielding CJ, Fielding PE. Molecular physiology ofreverse cholesterol transport. J Lipid Res 1995;36:211-28.
10. Tan KC. Reverse cholesterol transport in type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:534-43.
11. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001;15:2073-84. (Pubitemid 32927925)
12. Vohl MC, Neville TA, Kumarathasan R, et al. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation ofoxidized lipids during lipoprotein oxidation. Biochemistry 1999;38: 5976-81.
13. Howlader ZH, Kamiyama S, Shirakawa H, et al.Detoxification of oxidized LDL by transferring its oxidation product (s) to lecithin: cholesterol acyltransferase. Biochem Biophys Res Commun 2002;291:758-63. (Pubitemid 34694339)
14. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005; 112:879-84. (Pubitemid 41170075)
15. Ayyobi AF, McGladdery SH, Chan S, et al. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk ofvascular disease: 25 year follow-up. Atherosclerosis 2004;177:361-6. (Pubitemid 39505269)
16. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomar-ker and a pathogenic factor. Curr Opin Lipidol 2009;20:363-9.
17. Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endo-thelium-dependent arterial relaxation. Circ Res 1993;72:1103-9. (Pubitemid 23105515)
18. Quinn MT, Parthasarathy S, Fong LG, et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8. (Pubitemid 17064764)
19. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenic-ity. N Engl J Med 1989;320:915-24. (Pubitemid 19101597)
20. Nakhjavani M, Khalilzadeh O, Khajeali L, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010;45:321-7.
21. Bielicki JK, Forte TM, McCall MR. Minimally oxidized LDL is a potent inhibitor oflecithin: cholesterol acyltransferase activity. J Lipid Res 1996;37:1012-21.
22. Kamiyama S, Kim HJ, Furukawa Y. Inhibitory effects of oxidized low-density lipoprotein on the activity of plasma lecithin: cholesterol acyltransferase. Biosci Biotechnol Biochem 1996;60:580-3. (Pubitemid 126477687)
23. American Diabetes Association. Diagnosis and classification ofdia-betes mellitus. Diabetes Care 2008;31(suppl 1):S55-60.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9. (Pubitemid 15018832)
25. Akanji AO, Agbedana EO. Glycaemia and body mass as determinants of plasma lecithin: cholesterol acyltransferase activity in Nigerian patients with non-insulin dependent diabetes mellitus. Clin Chim Acta 1995;238:35-42.
26. Durucan M, Serdar Z, Sarand LE, et al. Lecithin: cholesterol acyltransferase activity and cholesteryl ester transfer rate in patients with diabetes mellitus. Turk J Med Sci 2003;33:95-101. (Pubitemid 36604408)
27. Riemens S, van Tol A, Sluiter W, et al. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-contain-ing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9. (Pubitemid 28378456)
28. Nakhjavani M, Esteghamati A, Esfahanian F, et al. HbA1c nega-tively correlates with LCAT activity in type 2 diabetes. Diabetes Res Clin Pract 2008;81:38-41.
29. Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 2007;50:643-53. (Pubitemid 46215509)
30. Fievet C, Igau B, Bresson R, et al. Non-enzymatic glycosylation of apolipoprotein A-I and its functional consequences. Diabete Metab 1995;21:95-8.
31. Vaziri ND, Liang K, Parks JS. Acquired lecithin-cholesterol acyl-transferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 2001;280:F823-8.
32. Krimbou L, Marcil M, Davignon J, et al. Interaction of lecithin: cholesterol acyltransferase (LCAT).alpha 2-macroglobulin complex with low density lipoprotein receptor-related protein (LRP). Evidence for an alpha 2-macroglobulin/LRP receptor-mediated system participat-ing in LCAT clearance. J Biol Chem 2001;276:33241-8.
33. Woodman RJ, Watts GF, Playford DA, et al. Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. Diabetes Obes Metab 2005;7:612-7. (Pubitemid 41150436)
34. Stephens JW, Gable DR, Hurel SJ, et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 2006;52:446-52.
35. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004; 53:297-302. (Pubitemid 38684688)
36. McCall MR, Tang JY, Bielicki JK, et al. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol 1995;15:1599-606.
37. Heinecke JW. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol 1997;8: 268-74. (Pubitemid 27462433)
38. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994;5:252-7. (Pubitemid 24249558)